A Phase 2 interventional study of zagociguat 15mg in Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome), sponsored by Tisento Therapeutics. Terminated at 16 sites in 5 countries. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Tisento Therapeutics · Phase 2, Interventional, and Treatment
Terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Acidosis, Lactic with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Acidosis, Lactic · United States.
Among the 19 studies in Acidosis, Lactic with a site in United States, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 2, and was the 19th registered.
48 studies on the registry are indexed under Acidosis, Lactic; 5 are open to participants now.
Browse Acidosis, Lactic studies →2 of the 19 studies in Acidosis, Lactic with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Canada
Healthy volunteers
George Washington University · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Acidosis, Lactic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7
First in 1978; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 39 across 26 interventional studies indexed under Acidosis, Lactic.
Median enrollment 29 across the 14 interventional studies, 35 across the 5 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 19 have an industry lead sponsor. The 10 most frequent:
Tisento Therapeutics is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Tisento Therapeutics has 2 studies filed under Acidosis, Lactic — fewer than ten, so there is no comparison to draw.
1 of the studies in Acidosis, Lactic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Acidosis, Lactic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed study medication treatment in the lead-in study TIS6463-203. TIS6463-204 is evaluating zagociguat in an open-label extension study at the daily dose of 15mg. The study medication is a once daily oral table and will be provided at the clinic and/or shipped to the participant's home. Study assessments will be conducted during clinic visits which will occur at three months and then at six months. Thereafter, clinic visits will occur every six months.
On Screening Visit Day -1 (which corresponds to Period 2 Week 12 Visit from lead-in study TIS6463-203), participants will sign the informed consent form, be confirmed eligible for this open-label extension study and undergo Screening Visit assessments. Eligible participants will begin dosing the next day on Day 1 (there is no Day 0) at home. Participants will have a 3-month visit and 6-month study visit at the clinic and thereafter will have a clinic visit every 6 months. Participants should have a Follow-up Visit 4 (+1) weeks after zagociguat discontinuation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Any medical condition or clinical finding that, per investigator judgement, would preclude safe study participation and/or completion of all trial requirements.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive zagociguat 15 mg once a day (QD) for the duration of the study.
Drug: zagociguat 15mg
once daily oral tablets
Also known as: IW-6463, CY6463
Incidence of Treatment-emergent Adverse Events (TEAEs)
TEAEs are any untoward event that may or may not be related to study medication.
Time frame: Day 1 through the Follow-up for treatment period 4 weeks after last dose of study medication.
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in Oct 2026, 14 months.
Primary completion moved twice since we started tracking on Sep 25, 2026: Jul 2028 → Oct 2026, last on Nov 6, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Jul 2028 → Oct 2026, last on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety.
Terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety.
On 5 October 2026 the study was terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zagociguat
Tisento Therapeutics